Consolidation Pembrolizumab Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC

NCT02343952 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

93

Enrollment

OTHER

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: Pembrolizumab

Sponsor

Nasser Hanna, M.D.

Collaborators

[object Object]
[object Object]